β-RA reduces DMQ/CoQ ratio and rescues the encephalopathic phenotype in Coq9R239X mice Hidalgo Gutiérrez, Agustín Barriocanal Casado, Eliana Bakkali, Mohammed Díaz-Casado, Elena Sánchez-Maldonado, Laura Romero Pérez, Miguel Sayed, Ramy K. A. Prehn, Cornelia Escames Rosa, Germaine Duarte Pérez, Juan Manuel Acuña Castroviejo, Darío López García, Luis Carlos Genetics Gene Therapy & Genetic Disease Pharmacology & Drug Discovery RNA-Seq data were generated as described above. The files have been uploaded in the repository Gene Expression Omnibus. The accession number is GSE120287. All data can be found at https:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120287. Coenzyme Q (CoQ) deficiency has been associated with primary defects in the CoQ biosynthetic pathway or to secondary events. In some cases, the exogenous CoQ supplementation has limited efficacy. In the Coq9R239X mouse model with fatal mitochondrial encephalopathy due to CoQ deficiency, we have tested the therapeutic potential of b-resorcylic acid (b-RA), a structural analog of the CoQ precursor 4-hydroxybenzoic acid and the anti-inflammatory salicylic acid. b-RA noticeably rescued the phenotypic, morphological, and histopathological signs of the encephalopathy, leading to a significant increase in the survival. Those effects were due to the decrease of the levels of demethoxyubiquinone-9 (DMQ9) and the increase of mitochondrial bioenergetics in peripheral tissues. However, neither CoQ biosynthesis nor mitochondrial function changed in the brain after the therapy, suggesting that some endocrine interactions may induce the reduction of the astrogliosis, spongiosis, and the secondary down-regulation of astrocytes-related neuroinflammatory genes. Because the therapeutic outcomes of b-RA administration were superior to those after CoQ10 supplementation, its use in the clinic should be considered in CoQ deficiencies. 2018-11-29T08:18:52Z 2018-11-29T08:18:52Z 2018-11-27 info:eu-repo/semantics/article Hidalgo-Gutiérrez, Agustín; et. al. β-RA reduces DMQ/CoQ ratio and rescues the encephalopathic phenotype in Coq9R239X mice. EMBO Mol Med (2018) e9466 [http://hdl.handle.net/10481/53973] http://hdl.handle.net/10481/53973 10.15252/emmm.201809466 eng http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess Atribución 3.0 España European Molecular Biology Organization (EMBO)